The emergence of targeted drugs has prolonged the survival time of NSCLC patients, especially for patients with favorable EGFR mutations and ROS1 and ALK-positive patients, and improved the patients' clinical prognosis and life quality. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.